Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 13, Issue 1, Pages 9-27Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2015.990382
Keywords
isavuconazole; pharmacodynamics; pharmacokinetics; systemic fungal infections
Funding
- Astellas Pharma B.V
- Gilead Sciences
- Merck B.V.
- Astellas Pharma B.V.
- Pfizer B.V.
Ask authors/readers for more resources
The prodrug isavuconazonium sulfate (BAL8557) is an extended-spectrum water-soluble triazole, developed for the treatment of severe invasive and life-threatening fungal diseases. Its active moiety, BAL4815, is a potent inhibitor of ergosterol biosynthesis, resulting in the disruption of fungal membrane structure and function. The active compound shows broad-spectrum of activity and potency against all major opportunistic fungi, such as Aspergillus spp., Candida spp., Cryptococcus spp., Mucorales, Black yeasts and their filamentous relatives and the true pathogenic fungi, including Histoplasma capsulatum and Blastomyces dermatitidis. It is currently in Phase III clinical development for treatment of aspergillosis, candidiasis and mucormycosis, as well as other rare fungi infections. We reviewed the pharmacokinetic and pharmacodynamic characteristics of isavuconazole, and its microbiological and clinical investigation progress in advanced stages of development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available